Product logins

Find logins to all Clarivate products below.


Key trends to watch:
Redefining targetability with protein degraders

Gain insights into the emerging potential of targeted protein degraders for ‘undruggable’ cancers.

Tackling hard-to-drug targets

Many diseases remain untreatable with conventional therapies because their underlying proteins lack sites for traditional small-molecule drugs. Targeted protein degradation offers a promising solution, harnessing the cell’s own systems to selectively eliminate pathogenic proteins.

PROTACs, molecular glue degraders and next-generation strategies like degrader-antibody conjugates, lysosome-targeting chimeras (LYTACs) and cereblon E3 ligase modulators (CELMoDs) could transform outcomes for cancers, autoimmune disorders and other hard-to-treat diseases.

Emerging viability of protein degraders in oncology

After nearly 70 years of protein degrader development, their viability as oncology treatments is finally being demonstrated, not only for better outcomes for patients with “undruggable” cancers but also in deal values. In 2024, nearly 20 deals totaling $13.25bn signaled growing industry confidence.

~40K
new cases of previously treated CLL and SLL were estimated in the G7 markets in 2025.

(Clarivate data)
~94K
new cases of relapsed or refractory multiple myeloma were estimated in the G7 markets in 2025.

(Clarivate data)
70 years
of targeted protein degrader development is finally being realized in the form of effective therapies.

(Clarivate data)

Promising degraders for oncology

The Drugs to Watch in this category represent the evolution in precision oncology resulting from increased sophistication in targeting disease mechanisms.

BGB-16673
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Mezigdomide
Multiple myeloma